MedTrace Logo

Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity

NCT01863459 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2017-08-02

No results posted yet for this study

Summary

1. To evaluate the safety, and efficacy of Lisdexamfetamine dimesylate in the treatment of outpatients with DSM-IV ADHD with anxiety and depressive disorder comorbidity, as well as to evaluate the effects on quality of life .
2. To evaluate the efficacy of Lisdexamfetamine dimesylate in the treatment of anxiety and depressive disorders which commonly occur with ADHD.
3. To examine the potential relationship between telomere length and Adult ADHD with comorbidity and the potential effect of treatment response.
4. To examine the potential associations with specific genes and Adult ADHD.

Conditions

  • Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders

Interventions

DRUG

Lisdexamfetamine Dimesylate

DRUG

placebo

Sponsors & Collaborators

  • Shire

    collaborator INDUSTRY

  • Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada

    lead OTHER

Principal Investigators

  • Stephen Collins, MBChB, FRCPC · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01863459 on ClinicalTrials.gov